01/27/23 8:47 AMNasdaq : CYTO low floatAltamira Therapeutics Provides Business Update Process for divestiture / partnering of legacy assets continues Strong data from Bentrio ® NASAR study reinforces its therapeutic benefit for allergic rhinitis Case for Bentrio’s protective effect in viral infection prophylaxis still intactRHEA-AIneutral
01/24/23 8:17 AMNasdaq : CYTO clinical triallow floatAltamira Therapeutics Provides Update on Clinical Trials with Bentrio Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal symptom primary endpoint over saline nasal spray comparator NASAR main trial phase completed; fullRHEA-AIneutral
01/10/23 8:47 AMNasdaq : CYTO conferenceslow floatAltamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26thCompany COO Dr. Pañeda will discuss SemaPhore TM platform’s functionality with mRNA, and: Peptide-based platform for extrahepatic delivery The extrahepatic success of, and prospects for, SemaPhore vs other liver-restricted delivery methodsRHEA-AIvery positive
12/19/22 8:47 AMNasdaq : CYTO low floatAltamira Therapeutics Provides Year-End 2022 Business Update Altamira Therapeutics Provides Year - End 2022 Business Update Strategic Bentrio TM partnering or divestiture process enters decisive phase Partnering or divestiture process for inner ear therapeutics assets ongoing Implementing newRHEA-AIneutral
12/02/22 8:47 AMNasdaq : CYTO clinical triallow floatAltamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in AustraliaAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicatedRHEA-AIneutral
11/30/22 8:47 AMNasdaq : CYTO earningslow floatAltamira Therapeutics Provides Business Update and First Half 2022 Financial ResultsBentrio TM nasal spray launched in Hong Kong by partner Nuance Pharma to help protect against viruses and allergens COVAMID trial with Bentrio in acute COVID-19 progressing towards read-out in December Strategic Bentrio partnering orRHEA-AIneutral
11/30/22 8:07 AMNasdaq : CYTO low floatAltamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance PharmaInitiative is Nuance’s first step in penetrating Chinese market with Bentrio TM Densely populated Hong Kong (7.3 million) remains negatively impacted by COVID-19 Nuance Pharma to file for marketing approval in Macao, Mainland China and SouthRHEA-AIneutral
11/22/22 8:47 AMNasdaq : CYTO low floatIn Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability• Animal study shows effective protection of mitochondria from oxidative damage and reduced plaque vulnerability in advanced atherosclerosis following treatment with SOD2 mRNA nanoparticles based on Altamira's SemaPhore™ technology • Data presented at American Heart Association Annual ScientificRHEA-AIneutral
11/10/22 8:47 AMNasdaq : CYTO conferenceslow floatAltamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event• TIDES Europe Event will be held on November 16-18, 2022, in Vienna, Austria • Company Chief Development Officer, Covadonga Pañeda, Ph.D., to present on the advantages of Altamira’s OligoPhoreTM / SemaPhoreTM RNA delivery technology • Dr.RHEA-AIneutral
11/09/22 8:47 AMNasdaq : CYTO low floatAltamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid RequirementAltamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs today announced that it has regained compliance with the Nasdaq listing requirements. On November 08, 2022 theRHEA-AIneutral